A Phase 2 interventional study of stereotactic radiosurgery and quality-of-life assessment in Fallopian Tube Cancer, Ovarian Sarcoma and Ovarian Stromal Cancer, sponsored by Case Comprehensive Cancer Center. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-28.
Sponsored by Case Comprehensive Cancer Center · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 589 studies in Fallopian Tube Neoplasms with a site in United States — 63 open to participants now, 130 under way, 24 of them phase 3. Fallopian Tube Neoplasms · United States.
Among the 589 studies in Fallopian Tube Neoplasms with a site in United States, this one is the 220th largest by enrollment of the 513 interventional ones that give a count, is one of 21 that started in 2009, is one of 211 in phase 2, and was the 207th registered.
835 studies on the registry are indexed under Fallopian Tube Neoplasms; 131 are open to participants now.
Browse Fallopian Tube Neoplasms studies →63 of the 589 studies in Fallopian Tube Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Israel, Taiwan
Ages 18+ · Women only
AstraZeneca · Sites in United States, Australia, Brazil and 10 more countries
Ages 18+ · Women only
Merck Sharp & Dohme LLC · Sites in United States, Israel, Korea, Republic of and 2 more countries
Ages 18+ · Women only
University of Washington · Sites in United States
Ages 18+ · Women only
AstraZeneca · Sites in United States, Argentina, Australia and 26 more countries
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 106 Fallopian Tube Neoplasms studies recruiting now, 88 (83%) set no upper age limit and 10 (9%) stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
589 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 239 · Phase 2 275 · Phase 3 60
First in 1992; this study’s year is marked. 21 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is close to the median of 50 across 684 interventional studies indexed under Fallopian Tube Neoplasms.
Median enrollment 40 across the 513 interventional studies, 119 across the 45 observational. Of the 420 that completed or were terminated, 202 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
170 of 589 have an industry lead sponsor. The 10 most frequent:
Case Comprehensive Cancer Center is the lead sponsor of 495 studies on the registry; 60 are open to participants now.
Of its 75 completed or terminated interventional studies of FDA-regulated products, 46 (61%) have results posted.
Case Comprehensive Cancer Center has 4 studies filed under Fallopian Tube Neoplasms — fewer than ten, so there is no comparison to draw.
39 of the studies in Fallopian Tube Neoplasms with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05281471Phase 3Genelux CorporationEfficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | 2026-12 |
| NCT04498117Phase 3CanariaBio Inc.Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | 2026-12-26 |
| NCT04095364Phase 3NRG OncologyLetrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | 2027-02-01 |
| NCT05445778Phase 3AbbVieMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | 2027-04 |
| NCT05456685AbbVieMirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer | 2026-11 |
Add all 39 to your calendar (.ics) → With an account.
Among the 589 studies in Fallopian Tube Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
RATIONALE: Stereotactic radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue.
PURPOSE: This clinical trial studies stereotactic radiosurgery using CyberKnife works in treating women with advanced or recurrent gynecological malignancies.
PRIMARY OBJECTIVES:
I. The primary goal of this study is to estimate the rate of grade 3 or higher acute toxicities observed during a 6 month period following CyberKnife radiosurgery for gynecologic cancers.
II. To evaluate clinical response to radio-surgery for gynecologic tumors.
III. To assess general and site specific quality of life (using SF-12, FACT-En, FACT-O, FACT-Cx or FACT-V) and to evaluate patient's level of pain.
SECONDARY OBJECTIVES:
I. As a secondary objective, toxicities during the 2 years following CyberKnife radiosurgery will also be described.
OUTLINE:
Patients undergo 3 fractions of CyberKnife stereotactic radiosurgery.
After completion of study treatment, patients are followed at 1, 3, 6, 12, 18 and 24 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergo 3 fractions of CyberKnife stereotactic radiosurgery.
Radiation: stereotactic radiosurgery · Procedure: quality-of-life assessment
Radiation will be delivered in 3 fractions. The dose level will range between 500 to 800cGy per fraction at the discretion of the treating radiation oncologist
Ancillary studies
Also known as: quality of life assessment
Acute Toxicity Rate
The incidence of grade 3 or 4 possible SBRT-related non-hematological toxicities observed during a 6 month period.
Time frame: at 6 months after treatment
Disease-free Survival
Median disease free survival
Time frame: completion of study at 24 months
Median Overall Survival
Length of time patients survived at study end.
Time frame: 24 months
Quality of Life
Time frame: After completion of study treatment, patients are followed at 1, 3, 6, 12, 18 and 24 months.
Clinical Response Rate
Percentage of patients with a clinical response following RECIST (Response Evaluation Criteria in Solid Tumors) Criteria: Confirmed complete response(CR), Stable disease (SD), partial response (PR), or without progressive disease (PD).
Time frame: at 6 months from study entry
Between July 24,2009 and September 7, 2011, 50 patients were recruited from University Hospitals in Cleveland Ohio.
| Milestone | Arm I: CyberKnife Radiosurgery |
|---|---|
| Started | 50 |
| Completed | 49 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
The incidence of grade 3 or 4 possible SBRT-related non-hematological toxicities observed during a 6 month period.
| percentage of participants | Arm I: CyberKnife Radiosurgery |
|---|---|
| Acute Toxicity Rate | 6 |
Median disease free survival
| months | Arm I: CyberKnife Radiosurgery |
|---|---|
| Disease-free Survival | 7.8 (4 to 11.6) |
Length of time patients survived at study end.
| months | Arm I: CyberKnife Radiosurgery |
|---|---|
| Median Overall Survival | 20.2 (10 to 29.5) |
No measurements were reported for this outcome.
Percentage of patients with a clinical response following RECIST (Response Evaluation Criteria in Solid Tumors) Criteria: Confirmed complete response(CR), Stable disease (SD), partial response (PR), or without progressive disease (PD).
| percentage of participants | Arm I: CyberKnife Radiosurgery |
|---|---|
| Clinical Response Rate | 68 (53 to 80) |
Collected over Adverse events were collected while patients were receiving treatment and during 6 months of follow up.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm I: CyberKnife Radiosurgery | — | 3/50 (6%) | 34/50 (68%) |
| Event | Arm I: CyberKnife Radiosurgery |
|---|---|
| Death not associated with CTCAE term - Disease progression NOSGeneral disorders | 1/50 |
| Bilirubin (hyperbilirubinemia)Investigations | 1/50 |
| ConfusionNervous system disorders | 1/50 |
| Event | Arm I: CyberKnife Radiosurgery |
|---|---|
| "Fatigue (asthenia, lethargy, malaise)"General disorders | 10/34 |
| HemoglobinBlood and lymphatic system disorders | 6/34 |
| NauseaGastrointestinal disorders | 6/34 |
| PlateletsBlood and lymphatic system disorders | 3/34 |
| DiarrheaGastrointestinal disorders | 3/34 |
| Pain - BackMusculoskeletal and connective tissue disorders | 3/34 |
| AnorexiaMetabolism and nutrition disorders | 2/34 |
| Pain - Abdomen NOSGastrointestinal disorders | 2/34 |
| Edema: limbGeneral disorders | 2/34 |
| CreatinineMetabolism and nutrition disorders | 2/34 |
| Age Continuous(years) | Arm I: CyberKnife Radiosurgery |
|---|---|
| Median | 66 (27 to 82) |
| Sex: Female, Male(Participants) | Arm I: CyberKnife Radiosurgery |
|---|---|
| Female | 50 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | Arm I: CyberKnife Radiosurgery |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 48 |
| Unknown or Not Reported | 2 |
| Race (NIH/OMB)(Participants) | Arm I: CyberKnife Radiosurgery |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 5 |
| White | 45 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Arm I: CyberKnife Radiosurgery |
|---|---|
| United States | 50 |
The record gives a start of May 2009, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2013, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Case Comprehensive Cancer Center →